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Rajinder P. S. Bajwa,5 Biju George,6 Vikas Gupta,7 Ricardo Pasquini,8 Hubert Schrezenmeier,9
Jakob R. Passweg,10 Kirk R. Schultz,11 Mary Eapen2The HLA class II DRB1 antigen DR15 (common alleles *1501, *1502) is an important marker in the patho-
biology of severe aplastic anemia (SAA). We studied 1204 recipients of HLA-matched sibling bone marrow
transplantation for SAA to determine whether HLA DR15 status (as determined by allele-level typing) af-
fected hematopoietic recovery, graft-versus-host disease (GVHD), or overall survival (OS). In multivariate
analysis, secondary graft failure rate at 2 years was lower in patients who were HLA DR151 (hazard ratio
5 0.46, P 5 .01). However, neutrophil recovery at day 228, platelet recovery at day 2100, acute GVHD,
chronic GVHD, and overall mortality were independent of DR15 status. The 5-year probabilities of OS, after
adjusting for age, race, performance score, transplant-conditioning regimen, and year of transplantation,
were 78% and 81% for patients who were HLA DR151 and HLA DR152, respectively (P5 .35). In conclu-
sion, DR15 status is associated with secondary graft failure after HLA-matched sibling bone marrow trans-
plantation for SAA but has no significant impact on survival.
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[1]. DR15 is involved in the pathobiology of T-lym-
phocyte-mediated marrow failure states such as severe
aplastic anemia (SAA), myelodysplastic syndromes,
and paroxysmal nocturnal hemoglobinuria [2-7].
Serologic HLA DR2, subsequently resolved as HLA
DR15 (or HLA DR16, respectively) by high-
resolution HLA typing, has been found to be overrep-
resented in patients with SAA in several ethnic groups.
Of the 30 different DR15 alleles, only *1501 and *1502
have been shown to have significantly higher frequen-
cies in SAA patients compared with the normal popu-
lation. Both common alleles of DR15, *1501 and
*1502, are associated with the pathogenesis of SAA,
with subtle differences; *1501 is associated with
PNH and *1502 is overrepresented in older patients
with SAA [8]. Diazepam-binding inhibitor-related
protein 1, a candidate autoantigen in SAA, has been
shown to be presented by DR15 [9].
The DR15 antigen is also reported to predict
response to immunosuppressive therapy in SAA,
although this is controversial [10-12]. Although the
exact mechanism for the association of HLA DR15
with autoimmune marrow failure states remains
unknown, it is thought that DR15 may play a role in1401
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Because epitope presentation also mediates the graft-
versus-leukemia effect, and susceptibility to immuno-
suppressive therapy may reflect the responsiveness of
graft-versus-host disease (GVHD) to treatment,
several groups have explored the impact of DR15 ex-
pression after HLA-matched sibling transplantation
for malignant diseases. These reports suggest lower
acute GVHD (aGVHD) and higher progression-free
survival in patients positive for DR15 (DR151)
[13-16]. Another explanation for immunobiologic
outcomes related to DR15 could be linkage
disequilibrium with other non-HLA immunogenetic
factors, such as tumor necrosis factor-alpha [17].
Given the involvement of DR15 in the pathobiology
of immunosuppression-responsive marrow failure
states and reports of DR15 impacting outcomes after
HLA-matched sibling transplantation for malignant
diseases, we examined whether outcomes after HLA-
matched sibling bone marrow transplantation for
SAA differed by HLA DR15 status.
MATERIALS AND METHODS
Data Source
Patient, disease and transplant characteristics, and
outcome data were reported to the Center for Interna-
tional Blood and Marrow Transplant Research
(CIBMTR). The CIBMTR is a voluntary working
group of over 400 transplant centers worldwide that
contribute data on consecutive hematopoietic trans-
plantations to a Statistical Center at the Medical
College of Wisconsin. All patients are followed longi-
tudinally, on an annual basis. The institutional review
boards of the Medical College of Wisconsin and the
NationalMarrowDonor Programapproved this study.
Inclusion Criteria
Included are patients with acquired SAA who un-
derwent HLA-matched sibling bone marrow trans-
plantation between 1990 and 2006. Patients with
secondary SAA, inherited bone marrow failure syn-
dromes, or abnormal karyotypes were excluded. Also
excluded were recipients of ex vivo T cell–depleted
bone marrow grafts, peripheral blood progenitor cells,
and unrelated donor transplantation. Selection was
confined to HLA-A-, -B-, and -DRB1-matched trans-
plantations to eliminate HLA-disparity as a driving
force for any observed differences. To avoid inclusion
of DR2 splits other than *15, we further confined the
study to those subjects for whom high-resolution
(allele-level) typing at the DR locus was available.
Outcomes
Time to neutrophil recovery was defined as the first
of 3 consecutive posttransplantation days that the
absolute neutrophil count was $0.5  109/L. Patientswho failed to achieve absolute neutrophil count
$0.5 109/Lwere considered tohavehadprimarygraft
failure. Secondary graft failure at 2 years was defined as
the sustained loss of neutrophil counts to\0.5 109/L
after initial neutrophil recovery or autologous reconsti-
tution. Time to platelet recovery was defined as the first
day of counts $20  109/L without transfusion for 7
days. Acute GVHD and chronic GVHD (cGVHD)
were defined according to the standard criteria [18].
Surviving patients were censored at last follow-up.
Death from any cause was considered an event.
Statistical Analysis
Patient-, disease-, and transplant-related factors
were compared between the DR151 and the DR152
groups using the chi-square test for categoric variables
and the Mann-Whitney test for continuous variables.
The probabilities of hematopoietic recovery and
aGVHDand cGVHDwere calculated using the cumu-
lative incidence function estimator to treat death with-
out the event as the competing risk [19]. The
probability of overall survival (OS)was calculated using
theKaplan-Meier estimator [20]. Risk factors for trans-
plant outcomes were identified through a stepwise for-
ward/backward model selection procedure. Cox
proportional hazard regression models [21] were built
for overall mortality, grade 2-4 aGVHD, and cGVHD
[22,23]. A logistic regression model using the
pseudovalue approach [24,25] was built for
hematopoietic recovery and secondary graft failure.
Variables that attained a P value #.05 were held in
the final multivariate models. The variable for DR15
status (DR 151 versus DR 152) was retained in all
steps of model building and the final model
regardless of significance level. Other variables tested
were: age (#20 versus 21-40 versus .40 years),
Karnofsky performance score (#80% versus 90%-
100%), time from diagnosis to transplantation (#3
versus .3 months), immunosuppressive therapy (yes
versus no), red blood transfusion (\20 versus 20-50
versus .50), conditioning regimen (cyclophosphamide
[Cy] 1 antithymocyte globulin [ATG] versus Cy
alone versus Cy 1 limited field irradiation versus
busulfan [Bu] 1 Cy versus fludarabine-containing
regimens), donor–recipient gender match (female
donor/male recipient versus others), donor–recipient
cytomegalovirus serostatus (donor and recipient sero-
negative versus donor and/or recipient seropositive),
and year of transplantation (1990-1995 versus 1996-
2000 versus 2001-2006). All variables were tested to en-
sure they met the proportional hazard assumption.
Variables that did not meet this assumption were ad-
justed by stratification; interval fromdiagnosis to trans-
plantation did not meet the assumption; consequently,
the model for overall mortality was stratified for this
variable. All P values are 2 sided. Analyses were per-
formed using SAS version 9.1 (SAS Institute,Cary,NC).
Table 1. Characteristics of Patients by HLA DRB1 Antigen
DR15 Status
Variable DR152 DR15+
P
Value
Number of patients 856 348
Patient related:
Age, median (range), years 18 (<1-61%) 21 (<1-58%) <.001
Age at transplantation, years <.001
#20 528 (62%) 164 (47%)
21-40 272 (32%) 151 (43%)
$40 56 (7%) 33 (9%)
Sex .37
Male 510 (60%) 217 (62%)
Female 346 (40%) 131 (38%)
Karnofsky score
pretransplantation
.50
<90 308 (36%) 120 (34%)
$90 534 (62%) 225 (65%)
Unknown 14 (2%) 3 (1%)
Disease related:
Time from diagnosis to
transplantation, months
3 (<1-263%) 3 (<1-232%) .74
Time from diagnosis to
transplantation, months
.29
#3 476 (56%) 192 (55%)
>3 380 (44%) 155 (45%)
Unknown 0 1 (<1%)
Immunosuppresive therapy
pretransplantation
.52
No 464 (54%) 193 (55%)
Yes 387 (45%) 151 (43%)
Unknown 5 (1%) 4 (1%)
Transplant related:
Conditioning regimen .04
Cyclophosphamide + ATG 546 (64%) 189 (54%)
Cyclophosphamide alone 128 (15%) 54 (16%)
Cyclophosphamide + limited
field irradiation ± ATG
20 (2%) 14 (4%)
Busulfan + cyclophosphamide ±
ATG
111 (13%) 67 (19%)
Fludarabine +
cyclophosphamide ± ATG
26 (3%) 12 (4%)
Fludarabine + busulfan ± ATG 17 (2%) 7 (2%)
Fludarabine + low-dose
TBI/limited field irradiation ±
other
2 (<1%) 1 (<1%)
Others 6 (1%) 4 (1%)
ATG .01
No 318 (37%) 156 (45%)
Yes 538 (63%) 192 (55%)
Donor–recipient gender match .35
Female donor–male recipient 224 (26%) 91 (26%)
Others 631 (74%) 255 (73%)
Unknown 1 (<1%) 2 (1%)
Donor–recipient CMV serostatus .10
Donor (+) and recipient (+) 416 (49%) 197 (57%)
Donor (+) and recipient (2) 40 (4%) 22 (6%)
Donor (2) and recipient (+) 127 (15%) 34 (10%)
Donor (2) and recipient (2) 216 (25%) 68 (19%)
Not tested/inconclusive/
unknown
57 (7%) 27 (8%)
Year of transplant .16
1990-1995 110 (13%) 33 (9%)
1996-2000 387 (45%) 174 (50%)
2001-2006 359 (42%) 141 (41%)
GVHD prophylaxis .38
Cyclosporine + methotrexate +
other
748 (87%) 297 (85%)
Cyclosporine ± other 82 (10%) 40 (11%)
Tacrolimus ± other 22 (3%) 7 (2%)
Tacrolimus alone 4 (<1%) 4 (1%)
CMV indicates cytomegalovirus.
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Patients and Characteristics
One thousand two hundred four patients with SAA
who underwent HLA-matched sibling bone marrow
transplantation were reported to the CIBMTR, and
all patients had high-resolution typing at DRB1 avail-
able. Three hundred forty-eight patients (29%) were
DR 151 and 856 patients (71%), DR152. All patients
received bone marrow grafts, and the median total
nucleated cell dose in both treatment groups was 3 
108/kg. The characteristics of patients, their diseases,
and transplantations are shown in Table 1. Character-
istics were similar except that patients with DR151
were slightly older than patients whowereDR152. Pa-
tients whowereDR152weremore likely to receive the
cyclophosphamide 1 ATG transplant conditioning
regimen and receive ATG. Seven patients were homo-
zygous for DR15 and were included within the DR15
heterozygous group. Themedian follow-up of patients
in both groups was 5 years.
Hematopoietic Recovery
The day 28 probabilities of neutrophil recovery
were 87% (95% confidence interval [CI] 84-89)
and 87% (95% CI 82-90) in patients who were
DR152 and DR151, respectively. The correspond-
ing probabilities of platelet recovery at day 100
were 89% (95% CI 87-91) and 88% (95% CI 84-
91). In multivariate analysis, there were no significant
differences in neutrophil recovery at day 28 or plate-
let recovery at day 100 in patients who were HLA
DR151 or HLA-DR152 (Table 2). The likelihood
of neutrophil recovery was higher in patients age
20-40 years compared with those age\20 years and
for transplantations that employed in vivo T cell de-
pletion with ATG. Karnofsky performance scores of
90 or 100 at transplantation were associated with
higher platelet recovery rates, whereas immunosup-
pressive therapy and red blood cell transfusions
$20 before transplantation lowered the likelihood
of platelet recovery.
Secondary graft failure was associated with DR
status; the likelihood of secondary graft failure at 2
years was significantly lower in patients who were
HLA DR151 compared with those who were HLA
DR152 (Table 2). Seventy-nine of 708 HLA
DR152 patients had secondary graft failures com-
pared with 21 of 316 patients with HLA DR151
(P 5 .03). Graft failure risks varied with transplant
conditioning regimen. Compared with patients who
received cyclophosphamide1 ATG, risks were higher
in patients who received cyclophosphamide alone, Bu,
and Cy or fludarabine-based conditioning regimens.
The effect of the transplant conditioning regimen is
independent of DR status.
Table 2. Risk Factors for Hematopoietic Recovery and
Secondary Graft Failure
Outcome N
Odds Ratio
(95% CI) P Value
Neutrophil engraftment at day 28
DR152 831 1
DR15+ 341 1.05 (0.71-1.57) .80
Other significant covariates:
Age at transplant, years
#20 676 1
21-40 410 1.73 (1.16-2.59) .007
$40 86 1.77 (0.82-3.81) .15
ATG
No 469 1 <.001
Yes 703 2.36 (1.66-3.35) <.001
Platelet recovery at day 100
DR152 821 1
DR15+ 333 0.88 (0.56-1.37) .56
Other significant covariates:
Karnofsky score pretransplantation
<90 405 1 .001
$90 732 2.14 (1.43-3.22) <.001
Unknown 17 1.70 (0.21-13.53) .62
Immunosuppresive therapy
pretransplantation
No 636 1
Yes 511 0.63 (0.42-0.94) .03
Number of blood transfusions
<20 331 1
20-50 205 0.39 (0.21-0.71) .002
>50 166 0.44 (0.23-0.84) .01
Unknown 452 0.54 (0.31-0.96) .04
Secondary graft failure at 2 years
DR152 787 1
DR15+ 316 0.46 (0.24-0.86) .02
Other significant covariates:
Karnofsky score pretransplantation
<90 376 1 <.001
$90 710 0.69 (0.41-1.16) .16
Unknown 17 6.55 (2.10-20.47) .001
Conditioning regimen
Cyclophosphamide + ATG 682 1
Cyclophosphamide alone 167 2.04 (1.04-3.99) .04
Cyclophosphamide + limited field
irradiation ± ATG
31 0.62 (0.09-4.14) .62
Busulfan + cyclophosphamide 164 2.32 (1.17-4.60) .02
Fludarabine + other agents 59 3.88 (1.73-8.66) <.001
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The day 100 probabilities of grade 2-4 aGVHD
were similar in patients who were DR152 and
DR151; 15% (95% CI 13-18) and 15% (95% CI
12-19), respectively. In multivariate analysis, grade
2-4 aGVHD was not associated with HLA DR status
(Table 3). Similarly, cGVHD risks were not associated
with HLA DR status (Table 3). The 5-year probabili-
ties of cGVHD were also similar in patients who were
DR152 and DR151; 17% (95% CI 1-20) and 19%
(95% CI 15-23), respectively.Overall Mortality
Nine hundred sixty-eight patients were alive at last
follow-up. HLA DR status was not associated with
overall mortality (Table 3, Figure 1). However, mor-
tality risks were lower in patients with Karnofsky per-formance scores of 90 or 100 and transplantations
performed between 2001 and 2006. Overall mortality
was also associated with type of transplant-
conditioning regimen; mortality was lower after the cy-
clophosphamide1 ATG regimen compared with other
regimens. The 5-year probabilities of OS, adjusted for
age, performance score, conditioning regimen, and
transplantation period were 78% (95% CI 74%-83%)
for patients with DR151 and 81% (95% CI 78%-
83%) for patients with DR152 (P 5 .350). In the
absence of an association between HLA DR status and
survival advantage for either group, we did not explore
whether differences exist between *1501 and *1502.DISCUSSION
The current analysis was undertaken to determine
the clinical impact of HLA DR15 status in HLA-
matched sibling bone marrow transplantation for
acquired SAA. There were no differences in hemato-
poietic recovery, aGVHD, cGVHD, and OS between
patients with and without the DR151 antigen, after
adjusting for the other risk factors associated with
transplant outcomes. However, the likelihood of
secondary graft failure is higher in patients who are
HLADR152. Importantly, the higher secondary graft
failure in these patients did not lead to highermortality.
Autologous recovery after transplantation is associated
with transfusion independence, and second transplan-
tation is not routine. The reason for the association be-
tween secondary graft failure and DR15 status is
unknown, but it is possible to speculate that differential
antiviral responses could be responsible. Our observa-
tions are contrary to that reported for response after
immune suppressive treatment for SAAwhere response
rateswere higher in patientswhowereDR151.Our in-
ability to demonstrate differences in aGVHD and sur-
vival among those who areDR152 andDR151 is also
contrary to that reported after allogeneic transplanta-
tion for hematologic malignancies.
Although not the primary intent of this analysis,
multivariable modeling in this large group of patients
with SAA allows some generalizable conclusions
regarding outcomes. Our findings confirm and ex-
tend those reported by others; mortality risks were
higher after transplantation for older patients (.20
years) and those with performance scores \90 [26].
In addition, mortality risks varied with transplant
conditioning regimen; mortality was lower in pa-
tients who received cyclophosphamide 1 ATG.
However, this might be a simple consequence of
the practice of utilizing nonstandard conditioning
regimens for patients who are not ideal candidates
for HSCT. In the current analysis, fludarabine and
Bu-containing conditioning regimens were used for
older patients, performance score\90 and longer in-
tervals from diagnosis to transplantation. The
Figure 1. The probabilities of OS in patients who are DR151 and
DR152 adjusted for patient age, performance score, and transplant
conditioning regimen.
Table 3. Risk Factors for GVHD and Overall Mortality
Factor N
Relative Risk
(95% CI) P Value
Acute GVHD
DR152 850 1
DR15+ 346 0.88 (0.64-1.22) .44
Other significant covariates:
Age at transplant, years
#20 691 1 <.001
21-40 419 1.82 (1.32-2.50) <.001
$40 86 3.48 (2.26-5.37) <.001
Year of transplant
1990-2000 697 1 .003
2001-2006 499 0.62 (0.45-0.85) .003
Chronic GVHD
DR152 836 1
DR15+ 340 1.06 (0.78-1.44) .73
Other significant covariates:
Age at transplant, years
#20 673 1 <.001
21-40 416 2.30 (1.69-3.13) <.001
$40 87 3.01 (1.87-4.86) <.001
GVHD prophylaxis
CsA + MTX ± other 1024 1 .005
CsA ± other 117 1.98 (1.31-3.01) .001
FK506 ± other 35 0.94 (0.34-2.56) .90
Donor/recipient gender match
F-M 311 1
Others 865 0.72 (0.53-0.97) .03
Year of transplant
1990-2000 693 1
2001-2006 483 0.68 (0.49-0.93) .02
Overall mortality
DR152 837 1
DR15+ 344 1.17 (0.87-1.55) .27
Other significant covariates:
Age at transplant, years
#20 680 1 <.001
21-40 414 1.39 (1.04-1.86) .02
$40 87 2.79 (1.88-4.14) <.001
Karnofsky score pretransplantation
<90 415 1 <.001
$90 749 0.61 (0.47-0.79) <.001
Unknown 17 1.58 (0.64-3.92) .32
Conditioning regimen
Cyclophosphamide +ATG 722 1
Cyclophosphamide alone 180 1.26 (0.88-1.82) .21
Cyclophosphamide +limited
field irradiation ± ATG
34 2.09 (1.13-3.86) .02
Busulfan + cyclophosphamide 178 1.79 (1.27-2.52) .001
Fludarabine + other agents 67 2.97 (1.73-5.11) <.001
Year of transplant
1990-2000 689 1
2001-2006 492 0.59 (0.42-0.82) .002
CsA indicates cyclosporine; MTX, methotrexate.
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with conditioning regimens could also be a reflection
of patient characteristics.
Despite overall improvements in transplant out-
comes for severe aplastic anemia, graft failure remains
a significant complication, with an incidence of ap-
proximately 10% [27-29] and the frequent need to
resort to second transplantation [30]. Hematopoietic
stem cells belong to the select group of tissues that
are capable of presenting HLA Class II, and if DR15
expression on hematopoietic stem cells protects
against graft failure in the host-versus-graft direction,this may occur independently of an equivalent impact
in the graft-versus-host direction to reduce GVHD.
Our study was confined to HLA-matched sibling
transplants, and the role, if any, of DR15 in unrelated
or mismatched related donor transplantations cannot
be determined. In conclusion, although HLA DR15
presence lowered secondary graft failure rates, it did
not impact other outcomes, particularly survival after
HLA-matched sibling bone marrow transplantation
for acquired SAA.ACKNOWLEDGMENTS
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